Organization (Industry)
Xencor Inc
ClinicalTrials.gov lists Xencor Inc as lead sponsor of 30 trials. It has 188 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Xencor Inc: 30 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (88)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 7 |
| Colorectal Neoplasms | 6 |
| Ovarian Neoplasms | 6 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Carcinoma, Renal Cell | 5 |
Showing 5 of 88 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 6 |
| 2022 | 6 |
| 2021 | 3 |
| 2019 | 2 |
| 2018 | 3 |
| 2016 | 6 |
| 2014 | 1 |
Showing 10 of 12 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 22 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (188)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| XmAb20717 | Prostatic Neoplasms | Phase 2 | 2 |
| XmAb20717 | Ovarian Neoplasms | Phase 2 | 2 |
| XmAb20717 | Uterine Cervical Neoplasms | Phase 2 | 2 |
| XmAb20717 | Fallopian Tube Neoplasms | Phase 2 | 2 |
| XmAb20717 | Endometrial Neoplasms | Phase 2 | 2 |
Showing 5 of 188 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Tafasitamab | 2 |
| LENALIDOMIDE | 1 |
| PEMBROLIZUMAB | 3 |
| IPILIMUMAB | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 33% hit target (n=15) | 63% on time (n=16) |
Journals published in (9)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Advances in therapy | 1 |
| Arthritis & rheumatology (Hoboken, N.J.) | 1 |
| Arthritis and rheumatism | 1 |
| Blood | 1 |
| Blood advances | 1 |
Showing 5 of 9 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 222 | 70 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 125,576,000 | -91,923,000 | 239,434,000 |
| 2024 | 110,493,000 | -232,618,000 | 227,686,000 |
| 2023 | 174,615,000 | -133,133,000 | 253,598,000 |
| 2022 | 164,579,000 | -55,181,000 | 199,563,000 |
| 2021 | 275,111,000 | 82,631,000 | 192,507,000 |
| 2020 | 122,694,000 | -69,333,000 | 169,802,000 |
| 2019 | 156,700,000 | 26,875,000 | 118,590,000 |
| 2018 | 40,603,000 | -70,409,000 | 97,501,000 |
| 2017 | 46,150,000 | -38,486,000 | 71,772,000 |
| 2016 | 109,020,000 | 45,125,000 | 51,872,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (20)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-29 | Royalty / licensing | not disclosed | Sec extracted |
| 2026-03-09 | Other financing | not disclosed | Sec extracted |
| 2026-02-25 | Follow-on offering | not disclosed | Edgar offerings |
| 2025-12-09 | Royalty / licensing | not disclosed | Sec extracted |
| 2025-06-12 | Other financing | not disclosed | Sec extracted |
Showing 5 of 20 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 58.0% | not disclosed |
Organization relationships (7)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Icon Plc | Uses vendor | 11 |
| Icon Plc | Co sponsors trial with | 3 |
| Parexel | Uses vendor | 1 |
| PPD Development, LP | Co sponsors trial with | 1 |
| PPD Development, LP | Uses vendor | 1 |
Showing 5 of 7 relationships.
Latest dated events (277)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-29 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-07-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-09 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-02-25 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 277 events.
Biomarker capability evidence (188)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| AR | Trial sponsor | Named in trial inclusion criteria |
| ARSI | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 188 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.